Skip to main content

Table 6 Effects of δ-tocotrienol treatment on "Regulator Effects" section (70) of IPA analysis of "Diseases and Functions" in hepatitis C patients

From: δ-Tocotrienol feeding modulates gene expression of EIF2, mTOR, protein ubiquitination through multiple-signaling pathways in chronic hepatitis C patients

ID Consistency Node Regulator Regulators Target Disease & Diseases & Functions Known Regulator-Disease/
  Score Total Total Total Fuunctions Totals Function Relationship
1 36.338 57 9 Ap1,CAMP,EIF2AK2,IL17A,IL1R,miR-155-5,STAT2 38 10 activation of phagocytes 48% (43/90)
2 32.199 69 13 26s Proteasome,ANGPT2,Ap1,BCL2,CAMP,CEBPA,TGFA 45 11 activation of antigen presenting cells 40% (57/143)
3 30.414 57 12 26s Proteasome,CAMP,CSF1,F2RL1,IL17A,miR-21-5p,TGFA 37 8 activation of myeloid cells 32% (31/96)
4 30.375 97 13 Ap1,CAMP,CCL5,EIF2AK2,F2RL1,FGF10,IL17A, 64 20 accumulation of l cells,leukopoiesis 38% (99/260)
5 28.605 56 10 26s Proteasome,BCL2,CAMP,STAT3,TGFA,TGM2 37 9 adhesion of blood cells 36% (32/90)
6 25.456 49 8 26s Proteasome,F2RL1,IL1RN,IRF4,KLF3,STAT3,TGFA, 32 9 adhesion of immune cells 26% (19/72)
7 25.126 127 20 ANGPT2,Ap1,CAMP,CST5,ETS1,F2RL1,IFNL1,IGF1,IL17A, 92 15 cell movement of granulocytes 40% (121/300)
8 24.82 53 8 26s Proteasome,BCL2,CSF1,F2RL1,IL1RN,STAT3,TGFA, 38 7 adhesion of blood cells 41% (23/56)
9 23.333 50 7 CAMP,F2RL1,IL17A,mir-10,NRG1,TGFA,Tlr 36 7 cell viability of tumor cell lines 63% (31/49)
10 23.026 36 7 26s Proteasome,BCL2,CREB1,F2RL1,IFNA2,IL1RN,TGFA 22 7 binding of leukocytes 24% (12/49)
11 22.687 55 11 26s Proteasome,Calcineurin protein(s),CD38,EIF4E,F2RL1, 37 7 migration of macrophages 23% (18/77)
12 21.651 23 5 CIITA,EBI3,IL27,PARP9,PDCD1 12 6 activation of lymphatic system cells 53% (16/30)
13 21.355 41 6 F2RL1,IL1RN,miR-155-5p (miRNAs w/seed UAAUGCU), 28 7 cell viability of mononuclear leukocytes 36% (15/42)
14 20.788 42 5 F2RL1,IL1RN,Pkc(s),TNFSF11,VEGFA 28 9 adhesion of immune cells 47% (21/45)
15 20.715 50 7 BTNL2,CIITA,Ifn,Ifnar,IL27,SYVN1,TGM2 33 10 activation of leukocytes 20% (14/70)
16 19.856 54 8 Ap1,CAMP,CSF2,EIF2AK2,F2RL1,IL1RN,miR-155-5p 39 7 chemotaxis of granulocytes 38% (21/56)
17 19.73 30 3 CAMP,miR-155-5p (miRNAs w/seed UAAUGCU),PSMD10 19 8 cell death of connective tissue cells 33% (8/24)
18 19.1 50 8 F2,F2RL1,IL17A,MIF,mir-1,PPRC1,REL,TGFA 35 7 cell viability of lymphatic system cells 46% (26/56)
19 18.764 67 13 Ap1,BCR (complex),CAMP,CSF2,IL12 (complex),IL21,STAT1, 48 6 synthesis of reactive oxygen species 41% (32/78)
20 18.475 41 7 F2RL1,IL17A,LDL,mir-1,PPRC1,REL,RELA 27 7 cell viability of mononuclear leukocytes 39% (19/49)
21 18.429 75 8 CCL5,F2RL1,IL1RN,miR-155-5pPSMD10,STAT4,TGFA 49 18 apoptosis of fibroblast cell lines 31% (45/144)
22 17.098 34 6 F2RL1,Igm,IL1RN,IL6,STAT3,VEGFA 23 5 binding of myeloid cells 37% (11/30)
23 16.585 33 7 CEBPA,EGF,FLT3LG,IL17A,MIF,mir-1,REL 21 5 NK cell proliferation 37% (13/35)
24 16.44 50 7 CAMP,F2RL1,IL17A,JUN,LDL,NRG1,TGFA 37 6 activation of antigen presenting cells, 50% (21/42)
25 15.167 50 7 CAMP,ETS1,F2,F2RL1,IL17A,MIF,TGFA 36 7 accumulation of cells 55% (27/49)
26 14.732 52 8 26s Proteasome,CSF1,IFNG,IL17A,IRF4,LDL,RELA,TGFA 39 5 chemotaxis of kidney cell lines 43% (17/40)
27 14.467 47 5 26s Proteasome,AKT1,LDL,TGFA,TGM2 37 5 cellular homeostasis 48% (12/25)
28 12.928 70 11 26s Proteasome,APP,CREB1,CSF1,IFNA2,IFNG,IL17A,TGFA 54 5 translation of mRNA 44% (24/55)
29 12.667 50 5 CEBPA,F2RL1,IL1RN,TNFSF11,VEGFA 36 9 quantity of IgG,recruitment of cells 31% (14/45)
30 12.33 50 7 CAMP,EIF2AK2,F2RL1,HRAS,IL17A,IL1RN,STAT2 37 6 homing of neutrophils,recruitment of cells 40% (17/42)
31 12.221 76 6 CD40LG,GAST,miR-155-5p,TNFSF11 63 7 production of reactive oxygen species 45% (19/42)
32 11.939 32 6 CAMP,ETS1,IL17A,KITLG,miR-155-5,miR-21-5p 22 4 infiltration by myeloid cells 38% (9/24)
33 11.839 34 4 BTNL2,Hbb-b2,Ifnar,TRIM24 24 6 diabetes mellitus,hypersensitive reaction 8% (2/24)
34 10.818 46 5 CEBPA,EGF,FLT3LG,IL17A,MIF 35 6 cell viability of tumor cell lines 43% (13/30)
35 9.707 21 5 F2,F2RL1,IL1RN,IL6,VEGFA 13 3 migration of antigen presenting cells 60% (9/15)
36 8.693 13 4 CD3,F2RL1,IL1RN,VEGFA 7 2 binding of myeloid cells 25% (2/8)
37 8.521 22 5 26s Proteasome,FOXO3,IL18,Pkc(s),TNFSF11 15 2 response of lymphatic system cells 60% (6/10)
38 8.01 74 8 A2M,CD40LG,GAST,mir-17,miR-17-5p,other miRNAs 58 8 anemia,binding of tumor cell lines 28% (18/64)
39 7.649 36 5 GAST,PARP9,PIK3R1,SOX4,TGFA 26 5 anemia,autophagy,organismal death 16% (4/25)
40 7.464 87 13 CD40LG,EP300,ERG,Igm,IL7,miR-19b-3p,miR-291a-3 69 5 cell death of fibroblast cell lines 28% (18/65)
41 7.181 14 6 CSF2,EDN1,F2,IL1B,KITLG,SPI1 7 1 migration of granulocytes 33% (2/6)
42 6.791 26 5 EDN1,F2,PRKCA,TNFSF11,VEGFA 17 4 Nephritis,synthesis of eicosanoid 40% (8/20)
43 6.633 17 3 IRF5,miR-155-5p (miRNAs w/seed UAAUGCU),PSMD10 11 3 apoptosis of connective tissue cells 0% (0/9)
44 6.379 18 3 ETS1,GFI1,PRL 13 2 quantity of hematopoietic progenitor cells 100% (6/6)
45 6.306 22 3 miR-155-5p (miRNAs w/seed UAAUGCU),miR-21-5p 17 2 cell death of connective tissue cells 17% (1/6)
46 6.183 27 3 CREB1,IFNA2,PDCD1 22 2 activation of leukocytes 67% (4/6)
47 5.667 14 1 GFI1 9 4 HIV infection,proliferation of blood cells 75% (3/4)
48 5.345 19 1 IL5 14 4 inflammation of body cavity 50% (2/4)
49 5.292 34 4 CAMP,CSF2,IFNG,IL12 (complex) 28 2 synthesis of leukotriene 75% (6/8)
50 4.907 17 3 EGF,PRDM1,SMARCA4 12 2 endocytosis,phagocytosis of cells 17% (1/6)
51 4.276 18 2 GFI1,Pkc(s) 14 2 differentiation of mononuclear leukocytes 50% (2/4)
52 4.199 37 3 IL2,IL21,IL4 30 4 apoptosis of connective tissue cells 42% (5/12)
53 4.16 17 3 CAMP,CSF1,Immunoglobulin 13 1 mobilization of Ca2+ 67% (2/3)
54 3.889 12 2 mir-8,miR-92a-3p (and other miRNAs w/seed AUUGCAC) 8 2 cell cycle progression 0% (0/4)
55 3.13 8 1 FOXO1 5 2 hyperplasia of lymphoid organ, 0% (0/2)
56 3.024 11 3 Igm,Interferon alpha,STAT1 7 1 apoptosis of kidney cell lines 0% (0/3)
57 3 13 3 CEBPA,IFN Beta,mir-223 9 1 production of protein 33% (1/3)
58 2.236 8 1 mir-223 5 2 Bacterial Infections,production of protein 0% (0/2)
59 1.789 7 1 E2F1 5 1 cell death of fibroblasts 100% (1/1)
60 1.789 7 1 IL15 5 1 cytotoxicity of natural killer cells 100% (1/1)
61 1.789 7 1 IL1B 5 1 binding of lymphatic system cells 100% (1/1)
62 1.732 5 1 CD28 3 1 hyperplasia of lymphoid organ 0% (0/1)
63 1.508 13 1 TP53 11 1 catabolism of protein 100% (1/1)
64 0.802 17 2 HRAS,TCR 14 1 expression of mRNA 0% (0/2)
65 0.577 32 4 IFNA2,IRF7,TGFB1,TNF 27 1 systemic lupus erythematosus 25% (1/4)
66 -2.714 13 1 IL4 11 1 infection of cells 100% (1/1)
67 -4.082 8 1 miR-21-5p (and other miRNAs w/seed AGCUUAU) 6 1 cell death 100% (1/1)
68 -6.5 6 1 TCF7L2 4 1 apoptosis of fibroblast cell lines 0% (0/1)
69 -16.743 5 1 TRAP1 3 1 synthesis of reactive oxygen species 100% (1/1)
70 -23.519 58 1 APP 56 1 cancer 100% (1/1)